Phytochemistry and Pharmacology of Bombax and Pseudobombax: Evidence-Based Insights and Current Limitations

1. Introduction

The use of medicinal plants continues to be a pivotal strategy for the discovery of bioactive compounds and the development of new therapeutic agents. Plant-derived metabolites have demonstrated significant pharmacological relevance, reinforcing the necessity of scientific validation for traditionally used species. Among plant families with recognized medicinal potential, Malvaceae stands out due to its wide distribution in tropical and subtropical regions and its richness in species capable of producing structurally diverse secondary metabolites [1].

Within this family, the genera Bombax and Pseudobombax (subfamily Bombacoideae) comprise large tropical tree species distributed mainly across Central and South America [2]. Species from these genera have been traditionally employed to treat inflammatory disorders, infections, metabolic diseases, and skin-related conditions. In recent years, experimental studies have reported several biological activities associated with extracts and isolated compounds, including antioxidant, anti-inflammatory, antimicrobial, cytoprotective, and metabolic regulatory effects [3,4,5]. These properties are frequently attributed to phenolic compounds, flavonoids, and terpenoids.

Despite the growing number of studies, scientific evidence regarding the phytochemical composition and pharmacological activities of Bombax and Pseudobombax remains fragmented. Most investigations focus on a limited number of species, particularly Bombax ceiba, while most of the genera remains poorly explored. Additionally, existing studies often evaluate different plant parts and employ heterogeneous experimental approaches, hindering direct comparisons and limiting broader conclusions regarding their pharmacological relevance [6]. This gap is particularly evident in high-biodiversity regions, such as Brazil, where native species represent a vast, yet underexplored, reservoir of bioactive molecules [7,8].

Considering these limitations, the present study aims to compile and critically analyze the available literature on the phytochemical constituents and experimentally validated pharmacological activities of Bombax and Pseudobombax. This narrative review seeks to address the following questions: (i) which pharmacological activities present the strongest experimental evidence; (ii) which species and plant parts remain underexplored; and (iii) what are the main gaps that should guide future phytochemical and pharmacological investigations. Ultimately, this work intends to contribute to a better understanding of the therapeutic potential of these genera and support future efforts in natural product discovery.

2. Materials and Methods

2.1. Study Design

This study was conducted as a narrative literature review aiming to compile and critically analyze available scientific evidence regarding the phytochemical constituents and pharmacological activities of species belonging to the genera Bombax and Pseudobombax. The narrative review approach was selected due to the heterogeneity of experimental designs, plant parts evaluated, extraction methods, and biological models reported in the literature, which limits the applicability of systematic review methodologies and meta-analysis. Although this approach allows broader conceptual interpretation, it may present limitations related to study selection bias and variability in methodological quality.

2.2. Literature Search Strategy

The literature search was conducted between March and December 2025 using the PubMed and ScienceDirect databases, considering their relevance in pharmacology, phytochemistry, ethnopharmacology, and natural product research.

The following descriptors were used:

• “Bombax”
• “Bombax AND pharmacological activity”
• “Pseudobombax”
• “Pseudobombax AND pharmacological activity”

Search terms were combined using Boolean operators (“AND” and “OR”) to expand the retrieval of relevant publications. Only studies published between 2013 and 2025 and written in English were considered.

2.3. Eligibility Criteria

Studies were selected based on the following criteria: (i) presentation of experimental evaluation of biological or pharmacological activities; (ii) investigation of extracts, fractions, or isolated compounds from Bombax or Pseudobombax species; (iii) availability of full-text access; and (iv) publication as peer-reviewed original research articles.

Studies were excluded if they: (i) mentioned the target genera only superficially; (ii) lacked experimental biological or pharmacological data; or (iii) were conference abstracts, editorials, or duplicated publications. Review articles were excluded to prioritize primary experimental data; however, relevant reviews were consulted to support the contextual interpretation and discussion of findings.

2.4. Study Selection Process

The initial search identified 1,702 publications related to Bombax and 270 publications related to Pseudobombax. After applying the defined temporal filter (2013–2025), 1,173 studies related to Bombax and 168 related to Pseudobombax remained.

Titles and abstracts were screened to evaluate relevance according to the eligibility criteria. Following this step, 31 articles involving Bombax species and 6 articles involving Pseudobombax species were selected for full-text analysis and data extraction.

A flow chart summarizing the study selection process is presented in Figure 1.

2.5. Data Extraction and Synthesis

All selected studies underwent full-text analysis. Data were extracted and systematically organized into a descriptive matrix comprising the following variables:

• Botanical species investigated;
• Plant part(s) utilized;
• Type of extract, fraction, or isolated compound;
• Biological or pharmacological activity evaluated;
• Experimental model employed (in vitro, in vivo, or in silico);
• Identified bioactive compounds (when applicable).

Subsequently, the gathered information was qualitatively categorized and synthesized to identify patterns of pharmacological activity, phytochemical diversity, and potential research gaps within the field.

2.6. Assessment of Evidence Quality

Due to the diversity of experimental approaches, a formal risk-of-bias tool was not applied. Instead, the overall quality of evidence was assessed qualitatively by considering the experimental models used, reproducibility of findings, and level of biological validation.

Most studies involved in vitro assays or animal experimental models, with limited clinical validation. Additionally, considerable variability was observed regarding extraction methods, phytochemical characterization, and pharmacological protocols, which restricts direct comparison between studies and highlights the need for standardized experimental designs in future investigations.

2.7. Hierarchical Classification of Evidence Strength

To contextualize the robustness of the available data and to avoid overstatement of therapeutic potential, the reported biological activities were classified according to experimental depth (Table 1). This hierarchical framework allows a structured interpretation of the evidence beyond mere frequency of reported activities.

3. Results

3.1. Study Identification and Selection

By December 2025, the initial database search identified 1,702 publications related to the genus Bombax and 270 related to Pseudobombax (Figure 1). Following the application of temporal and eligibility criteria, 1,173 and 168 articles remained, respectively. Subsequent screening of titles and abstracts led to the selection of 31 Bombax species articles and 6 Pseudobombax species articles for full-text analysis. Ultimately, only 37 studies met the inclusion criteria for qualitative synthesis, representing approximately 2.6% of the initially screened Bombax records and approximately 3.5% of the Pseudobombax records. This significant reduction (Figure 1) underscores the paucity of studies specifically addressing phytochemical characterization coupled with experimentally validated pharmacological activity within the established scope.

3.2. General Characteristics of the Evidence Base

A structured synthesis of the included studies (encompassing investigated species, plant organs, extraction strategies, phytochemical profiling, and reported biological activities) is detailed in Table 2 and Table 3 and visually summarized in Figure 2 and Figure 3. The overall evidence landscape reveals a marked asymmetry between the two analyzed genera.

Of the 37 included studies, 83.7% focused on Bombax, while only 16.2% investigated Pseudobombax, demonstrating a pronounced taxonomic imbalance. Within Bombax, B. ceiba predominated with 28 publications, representing 90.3% of the genus-specific research and 75.7% of the total selected articles. Conversely, other species such as B. costatum and B. buonopozense were minimally represented. In the six studies involving Pseudobombax, the distribution was more equitable among P. ellipticum (33.3%), P. marginatum (33.3%), P. simplicifolium (16.7%) and P. parvifolium (16.7%), with no single species showing research dominance comparable to B. ceiba.

This concentration pattern suggests that research efforts have been driven primarily by historical usage, geographic accessibility, and legacy phytochemical data rather than by systematic taxonomic or comparative strategies. Consequently, pharmacological generalizations at the genus level remain constrained, particularly for Pseudobombax, where the evidence base is sparse.

The organ-specific distribution of biological activities for the genera Bombax and Pseudobombax are visually synthesized in Figure 2 and Figure 3, respectively. While these mappings underscore a multifaceted pharmacological profile, the broader evidence landscape reveals a significant taxonomic disparity. Regarding plant morphology, leaves, flowers, and stem bark were the most frequently investigated organs overall. However, this distribution varies strictly by taxa: Bombax species were evaluated across a wide range of plant parts (Figure 2), whereas Pseudobombax investigations remain largely restricted to stem bark and flowers (Figure 3). Such preference appears to reflect research convenience and geographic accessibility rather than demonstrated phytochemical superiority. Consequently, the scarcity of systematic organ-to-organ comparisons limits robust conclusions regarding tissue-specific bioactive potential, particularly for the less-studied Pseudobombax.

Methodological heterogeneity was also pervasive across literature. Experimental designs varied significantly in extraction procedures, the depth of chemical characterization, and the selection of biological validation models. Several studies relied on crude extracts lacking standardized profiling, and inter-study comparability was often hindered by inconsistent reporting of experimental parameters. Such variability constrains reproducibility and complicates the integrative interpretation of pharmacological evidence.

Collectively, the current body of literature reveals a research landscape characterized by taxonomic concentration, organ-level selectivity, and methodological disparity. While both genera exhibit significant biological activity and phytochemical richness, the uneven distribution of investigative efforts highlights the urgent need for broader species coverage, standardized analytical profiling, and systematic comparative approaches.

3.3. Phytochemical Characterization: Analytical Scope and Depth

As summarized in Table 2 and Table 3, the phytochemical characterization of Bombax and Pseudobombax species revealed a predominance of phenolic compounds, flavonoids, tannins, alkaloids, terpenoids, and polysaccharides. Analytical characterization primarily relied on HPLC, LC–MS, and GC–MS platforms to identify secondary metabolites. While B. ceiba presented a more extensive profile, with repeated identification of mangiferin, beta-sitosterol, gallic acid, and lupeol, reporting for other species was considerably more limited. The analytical focus was largely qualitative, with most studies identifying major chemical classes without performing precise quantification of individual constituents.

Despite these technological advances, phytochemical reporting consistently exhibited critical methodological gaps, including:

• Lack of comprehensive quantitative profiling: Studies often focused on qualitative identification without determining compound concentrations.
• Non-standardized extraction protocols: High variability in solvent systems and extraction parameters limits inter-study comparability.
• Absence of batch reproducibility assessments: Minimal data exists regarding the chemical consistency of plant materials across different harvests or geographic locations.
• Underutilization of bioassay-guided fractionation: Systematic isolation strategies to identify active principles remain scarce.

In many instances, biological activities were attributed to broad chemical classes rather than structurally confirmed isolated compounds. Although compounds such as mangiferin, beta-sitosterol, gallic acid, lupeol, and various flavonoid derivatives were frequently identified in B. ceiba, a direct causal linkage between specific molecules and their pharmacological effects remain insufficiently demonstrated.

3.3. Genus Bombax

3.3.1. Biological Activities: Critical Appraisal of Experimental Evidence

The range of reported pharmacological activities is extensive (Table 2); however, the depth of experimental validation varies substantially across the literature.

3.3.2. Antioxidant Activity

Antioxidant capacity represents the most frequently evaluated biological property (Figure 2). Nevertheless, most studies relied on chemical-based assays, such as DPPH, ABTS, and FRAP, which measure radical-scavenging capacity in vitro but do not necessarily translate to physiological redox modulation. Only a limited number of investigations evaluated in vivo oxidative stress biomarkers, and mechanistic insights into endogenous antioxidant signaling pathways (e.g., Nrf2/ARE) were rarely explored. Consequently, while antioxidant potential is consistently reported, its translational relevance remains largely unverified.

3.3.3. Antimicrobial and Antiviral Activities

Antimicrobial activity has been predominantly assessed via in vitro growth inhibition assays (Table 2). While inhibitory effects were observed against multiple pathogenic strains, there is a lack of data regarding pharmacokinetics, systemic toxicity, or efficacy in in vivo infection models. Similarly, antiviral activity (against respiratory syncytial virus - RSV) was demonstrated exclusively in cell-based systems. The absence of mechanistic elucidation and in vivo validation limits the extrapolation of these findings toward therapeutic applications.

3.3.4. Cytotoxic and Anticancer Effects

Cytotoxic effects against various tumor cell lines have been reported (Table 2). However, the evidence is frequently constrained by significant methodological limitations, including:

• Lack of selectivity indices: Failure to evaluate toxicity in non-tumoral (healthy) cell lines.
• Absence of mechanistic confirmation: Lack of data regarding apoptosis induction or cell cycle arrest pathways.
• Inadequate validation: Absence of in vivo tumor xenograft models.
• Pharmacological gaps: No assessment of pharmacodynamic or pharmacokinetic profiles.

As illustrated in Figure 2, cytotoxicity represents a secondary research focus compared to antioxidant screening. Therefore, current findings should be interpreted as preliminary cytotoxic screening rather than substantiated anticancer efficacy.

3.3.5. Metabolic and Organ-Protective Effects

Metabolic and organ-protective activities, including antidiabetic, antihyperlipidemic, nephroprotective, hepatoprotective, and antiosteoporotic effects, were primarily evaluated in rodent models (Table 2). Although improvements in biochemical surrogate markers were commonly observed, molecular pathway validation and target-specific analyses were frequently omitted. While specific secondary metabolites were hypothesized to drive these effects, the definitive molecular mechanisms and their direct targets remain insufficiently established.

3.3.6. Hierarchical Assessment of Evidence Strength

The hierarchical classification framework was applied to all included studies, resulting in the categorization of 23 distinct pharmacological activities (Table 4). Level II evidence predominated (34.8%) with Level I (34.8%), followed by Level III (21.7%), and Level IV (8.7%) (Table 4).

Although 69.6% of the reported activities (Levels I–II) involved in vivo experimental models, only 34.8% fulfilled the criteria for robust validation supported by established disease models and quantifiable biochemical or molecular biomarkers (Level I). Besides, no clinical-level evidence was identified among the included studies.

Activities classified as Level I were primarily associated with metabolic and organ-protective effects, including hypoglycemic, antihyperlipidemic, hepatoprotective, nephroprotective, anti-inflammatory, gastroprotective and osteogenic properties, generally employing validated in vivo models and objective biochemical endpoints. Level II activities comprised functional in vivo evidence lacking detailed mechanistic elucidation (e.g., antiobesity, antiarthritic, and antidepressant effects). Conversely, Level III evidence was largely restricted to in vitro systems, particularly antioxidant and antibacterial assays, which represent a substantial proportion of the exploratory investigations (Figure 2 and Figure 3). Level IV corresponded to preliminary validation, such as ex vivo or isolated cellular systems without systemic confirmation.

3.4. Genus Pseudobombax

3.4.1. Biological Activities: Critical Appraisal of Experimental Evidence

The range of reported pharmacological activities for Pseudobombax is markedly more restricted compared to Bombax (Table 3), with research efforts concentrated on a limited number of species and plant organs.

3.4.2. Antioxidant Activity

As illustrated in Figure 3, antioxidant capacity is one of the few properties investigated for this genus. Like the trends observed in Bombax, these evaluations relied almost exclusively on in vitro radical-scavenging assays (e.g., DPPH and ABTS). There is an absence of in vivo redox modulation studies or mechanistic investigations into cellular antioxidant pathways. Consequently, the antioxidant potential of Pseudobombax remains at a preliminary screening stage, lacking physiological validation.

3.4.3. Antimicrobial Activity

Antimicrobial investigations in Pseudobombax are largely confined to in vitro assessments of stem bark extracts (Table 3). Although inhibitory effects against specific bacterial strains have been identified, the evidence base lacks diversity in tested pathogens and is devoid of in vivo efficacy trials, toxicity profiles, or pharmacokinetic data. No antiviral activities were identified for this genus within the evaluated timeframe.

3.4.4. Anti-Inflammatory and Antinociceptive Effects

A significant portion of the research on Pseudobombax (mainly P. marginatum) focuses on anti-inflammatory and antinociceptive properties. While these studies often employ in vivo functional models, such as paw edema or writhing tests, they frequently lack molecular depth. The specific mediators involved and the potential modulation of signaling pathways (e.g., COX-2 or cytokine cascades) remain insufficiently characterized.

3.4.5. Other Biological Properties

Other reported effects, such as anti-sickling and cytoprotective activities, represent isolated investigative efforts (Figure 3). These findings, while promising, are predominantly based on in vitro or ex vivo models without systemic confirmation. The lack of broader pharmacological screening across different plant parts, such as leaves or roots, limits the understanding of the genus's full therapeutic potential.

3.4.6. Hierarchical Assessment of Evidence Strength

The hierarchical classification of Pseudobombax research highlights a fragmented evidence landscape. In contrast to Bombax, where Level I evidence is more prevalent, Pseudobombax studies are largely situated at Levels II and III (Table 5).

• Level II: Predominates in studies concerning anti-inflammatory and antinociceptive effects, where in vivo functional efficacy is demonstrated but mechanistic details are sparse.
• Level III: Comprises the bulk of antioxidant and antimicrobial research, restricted to in vitro systems with low translational predictability.
• Level IV: Includes preliminary reports on anti-sickling and specific cellular protective effects lacking systemic validation.

Collectively, this distribution (Figure 3) reveals that the evidence base for Pseudobombax is not only smaller in volume but also lower in hierarchical strength. The reliance on a few species and the focus on stem bark research emphasize a significant taxonomic and morphological bias, precluding robust generalizations at the genus level.

4. Discussion

The present systematic review reveals not merely a disparity in research volume between Bombax and Pseudobombax, but a structural imbalance in scientific maturity, mechanistic depth, and translational progression. Although both genera display a wide array of reported biological activities, the evidence landscape is unevenly distributed, with research efforts disproportionately concentrated on a limited number of species and plant organs. This dual taxonomic and morphological bias restricts a comprehensive pharmacological interpretation of these taxa and may obscure chemically distinct and therapeutically relevant species that remain underexplored.

Within Bombax, the overwhelming predominance of B. ceiba likely reflects its broad geographical distribution and long-standing incorporation into traditional Asian medical systems [6]. However, this concentration has shaped the pharmacological identity of the genus in a way that may not accurately represent its internal chemical diversity. While B. ceiba demonstrates relatively advanced experimental validation in metabolic, organ-protective, and osteogenic contexts, other species such as B. costatum and B. buonopozense remain largely confined to functional screening stages. This imbalance narrows phytochemical discovery pipelines and limits opportunities to identify structurally novel metabolites potentially restricted to less-investigated taxa. From a drug discovery perspective, this concentration represents a clear constraint on chemical diversification and translational innovation.

A similar bias is evident at the morphological level. Leaves, flowers, and stem bark dominate the experimental landscape across both genera. Although ethnobotanical guidance partially explains this preference, methodological convenience appears equally influential. As discussed by Penido et al. [43], these organs are readily accessible and, in the case of bark and leaves, often available year-round, facilitating repeated experimental use. Nevertheless, the scarcity of systematic organ-to-organ comparative studies precludes definitive conclusions regarding tissue-specific bioactive superiority. Importantly, flowers are metabolically specialized structures enriched in flavonoids and anthocyanins [44], and the antisickling activity reported in Pseudobombax flowers underscores how underexplored organs may harbor clinically relevant bioactivities. Conversely, the predominant use of stem bark, particularly in Pseudobombax, raises sustainability concerns, as excessive harvesting can compromise plant viability and ecological balance [45]. These findings reinforce the necessity of aligning pharmacological exploration with conservation-aware research strategies.

Perhaps the most consequential finding of this review is the persistence of a pronounced translational gap. Antioxidant activity represents the most frequently reported biological property across both genera; however, its predominance is largely driven by chemical assays such as DPPH and ABTS, which provide limited physiological relevance. The reliance on rapid screening methodologies reflects a broader research paradigm oriented toward exploratory bioactivity detection rather than mechanistically grounded pharmacological development. In Bombax, several biological properties have progressed beyond this stage into validated in vivo models supported by biochemical and histological endpoints, suggesting a more advanced position along the preclinical validation continuum. In contrast, Pseudobombax remains predominantly positioned in early investigative phases, with activities frequently lacking systemic confirmation, molecular target identification, or pharmacokinetic characterization. Although both genera exhibit methodological limitations in extract standardization and pathway-level analysis, these constraints are more structurally limiting for Pseudobombax, where foundational translational infrastructure remains insufficiently developed.

Collectively, this asymmetry delineates two distinct developmental trajectories. Bombax represents a genus with consolidating pharmacological credibility that now requires deeper mechanistic refinement and chemical standardization to sustain translational progression. Pseudobombax, in contrast, emerges as a largely untapped phytochemical reservoir situated at the threshold of systematic exploration. Advancing the field will require a deliberate transition from repetitive exploratory screenings toward integrated, mechanism-oriented investigations combining phytochemical fingerprinting, target-based validation, and pharmacokinetic assessment. Expanding taxonomic coverage beyond B. ceiba, implementing comparative organ profiling, and strengthening molecular-level confirmation are essential to transform descriptive evidence into clinically meaningful insight.

Ultimately, the current body of literature reflects not the full pharmacological potential of Bombax and Pseudobombax, but rather the limitations of prevailing investigative paradigms. Bridging this gap demands a strategic reorientation from exploratory abundance to mechanistic precision. Only through such a shift can these genera transition from ethnopharmacological relevance to evidence-driven candidates within the modern drug discovery framework.

5. Conclusions

This systematic review provides a comprehensive and hierarchically structured appraisal of the pharmacological evidence available for the genera Bombax and Pseudobombax, revealing a pronounced asymmetry in research depth, taxonomic coverage, and translational maturity. While Bombax, particularly B. ceiba, exhibits a relatively advanced preclinical evidence profile supported by validated in vivo models and biochemical endpoints, the genus remains heavily centralized around a single species, limiting broader phytochemical and pharmacological generalization. In contrast, Pseudobombax is positioned at an earlier stage of scientific development, with most activities confined to exploratory or functionally descriptive investigations that lack mechanistic and pharmacokinetic refinement.

Across both genera, antioxidant activity predominates; however, it is largely anchored in chemical assays with limited physiological correlation, highlighting a persistent translational gap between in vitro screening and clinically relevant validation. Additionally, the preferential investigation of specific plant organs, particularly stem bark and flowers, reflects methodological and ethnobotanical influences rather than systematic phytochemical comparisons, raising both scientific and sustainability concerns regarding plant survival.